Core Viewpoint - Zhaoke Ophthalmology-B (06622) reported a significant decline in revenue and an increase in net loss, while advancing its drug candidates towards commercialization [1] Financial Performance - The company achieved revenue of HKD 15.803 million, a year-on-year decrease of 68.25% [1] - The net loss amounted to HKD 117 million, representing a year-on-year increase of 53.85% [1] Drug Development Progress - Three core drug candidates, including Atropine Sulfate Eye Drops, Cyclosporine Eye Gel, and Bevacizumab Vitreous Injection, have entered the New Drug Application (NDA) stage, with a goal of commercializing 12 drugs by the end of 2026 [1] Strategic Partnerships - Zhaoke Ophthalmology signed a distribution and supply agreement with PT Ferron Par Pharmaceuticals for its Atropine Sulfate Eye Drops in Indonesia, granting exclusive rights for import, promotion, distribution, marketing, and sales [1] - The agreement includes an upfront payment and potential milestone payments based on certain achievements [1]
港股异动 | 兆科眼科-B(06622)午后涨超8% 三款核心药物进入新药申请阶段 近期与PT Ferron达成战略合作